Acutaas Chemicals Limited
Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals and fine chemicals.
What Acutaas files
- Others57
- Investor Meet36
- Updates21
- Important12
- PPTs8
- Board Meeting5
**1. Business Performance:** Acutaas Chemicals started FY27 on a strong note, with Q1 revenue up 59.1% YoY to ₹329.7 Cr. Profit (PAT) jumped 70.4% YoY to ₹75.0 Cr, and EBITDA surged 122.1% YoY to ₹113.1 Cr. Growth was primarily driven by robust performance in CDMO and core Advanced Intermediates. Specialty...
Acutaas Chemicals delivered strong financial performance in FY26. **Business Performance:** Revenue from Operations surged to ₹1,339.4 Cr, a 33% year-on-year increase. Profit After Tax more than doubled to ₹356.4 Cr, marking a 122% jump. Pharmaceutical Intermediates remains the dominant segment, contributing 88% of revenue. The company also reported a robust...
Acutaas Chemicals reported a stellar Q4 FY26! Revenue jumped 40.3% YoY to ₹432.8 Cr. Profit After Tax (PAT) more than doubled, soaring 114.1% YoY to ₹134.3 Cr, achieving a record 31.0% PAT margin. Full-year FY26 revenue grew 33% to ₹1,339.4 Cr, with PAT up 122.2% to ₹356.4 Cr. Growth was...
Acutaas Chemicals reported strong Q3 FY26 results. 1. **Business Performance:** Revenue jumped 43% YoY to ₹393.2 Cr, driven by robust growth in Advanced Pharmaceutical Intermediates, especially from CDMO ramp-up. EBITDA soared 119.4% YoY to ₹150.7 Cr (38.3% margin), and Net Profit (PAT) surged 133.7% YoY to ₹106.2 Cr (27% margin),...
Acutaas Chemicals delivered robust Q2 FY26 performance, with revenue up 24.1% year-on-year to ₹306.2 Cr. This growth was primarily fueled by strong demand in Advanced Pharmaceutical Intermediates and steady contributions from Specialty Chemicals. For the half-year, revenue climbed 21% to ₹513.4 Cr. Profitability soared, with Q2 EBITDA jumping 94.8% to...